Introduction
and interferon (IFN)-␥ 9, 12 has been shown to abrogate Much evidence has been provided on the existence of tumorigenicity in syngeneic mice and to induce a long cytotoxic T lymphocytes (CTLs) specifically recognizing lasting T cell-mediated protective immunity. On these tumor-associated antigens (TAA), presented by HLAbases, cytokine gene therapy strategies have been proclass I molecules, in different human tumors. In recent posed for different human tumors and several protocols years, a growing number of CTL-defined TAA have been are in progress. 13 molecularly characterized, mostly in human melanoma, Small cell lung cancer (SCLC), which accounts for 18% and the structure of their antigenic peptides presented by of primary lung cancers is, in most instances, an specific HLA-class I alleles has been identified. 1 Some of incurable disease. 14 However, some evidence indicates these melanoma TAA appeared to be differentiation antithat the host immune response may play a role in the gens expressed by most melanomas as well as by normal natural history of SCLC. 15, 16 In addition, a clinical study melanocytes, while others were specific for individual suggested a possible efficacy of exogenous IL-2 in SCLC 17 melanomas. In addition to these TAA, three families of and IL-2-based gene therapy approaches have been progenes encoding for highly specific shared tumor antigens posed. 18 In a previous study, we have shown that IL-2 (MAGE, BAGE and GAGE) were identified and were gene transfection in SCLC cell lines abrogates tumorigenfound to be expressed not only in melanoma but also in icity in nude mice and that IL-2-transfected cells exert several other human tumors. [2] [3] [4] [5] [6] These studies provided local bystander effects on the growth of wild-type tumor the molecular basis for the development of different cells through the activation of nonspecific effector cells. 19 therapeutic approaches aimed to induce specific T cell Concerning the induction of specific T cell responses responses in human cancer. 1 against SCLC, mediating systemic immunity in patients, The transfer of cytokine genes into tumor cells has been it should be taken into account that frequently SCLC diswidely exploited to enhance tumor immunogenicity. 7, 8 In plays a reduced expression of HLA-class I molecules transplantable tumor models, engineering of tumor cells required for antigen peptide presentation to CTLs.
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To verify the possibility of inducing T cell responses against SCLC, we have analyzed the expression of HLA molecules and of CTL-defined antigens in a panel of of endogenous TAA to specific CTLs. Our results suggest The expression of HLA-class I antigens was analyzed by indirect immunofluorescence using the W6.32 mAb on the same panel of SCLC. As shown in Table 1 , expression of HLA class-I was sharply reduced or nearly undetectable, on most SCLC cell lines analyzed, as compared with normal lymphocytes. However, pretreatment of SCLC cell lines with exogenous IFN-␥ for 48 h was able to enhance HLA-class I surface expression significantly in all cell lines analyzed (ranging from four-to 100-fold, by comparing mean fluorescence intensity values), while no significant induction of HLA class II was observed (Table 1) . We further analyzed the effect of IFN-␥ gene transfection in cell lines (N592 and NCI-H69) selected on the basis of the presence of MAGE-3 and of the HLA-A2 allele, known to be involved in MAGE-3 antigen peptide presentation to CTLs. 21 As shown in Figure 2 , NCI-H69
Figure 2 RT-PCR analysis of IFN-␥ mRNA expression in NCI-H69 and Figure 1 RT-PCR analysis of MAGE-1, MAGE-3, BAGE and GAGE mRNA expression in SCLC cell lines. In the lower panel the same cDNAs
N592 parental and transfected cell lines. In the lower panel the same cDNAs were amplified using primers specific for ␤-actin. were amplified using primers specific for ␤-actin. Figure 4 ) and TAPthat the low amounts of IFN-␥ eventually secreted could act in an autocrine fashion, being trapped by surface 2 mRNA (not shown), which were undetectable in NCI-H69 and were very weakly expressed in N592 before receptors on the transfected cell. Moreover, staining with an anti-HLA-A2-specific mAb indicated that the transfection. expression of the A2 allele was also enhanced by IFN-␥ transfection, while no significant effects on surface HLA-MAGE-3 antigen presentation is restored by IFN-␥ transfection in SCLC cells class II molecules were observed. In experimental controls SCLC cell lines transfected with IL-2 gene (secreting In order to evaluate the effect of IFN-␥ gene transfection on the ability of the NCI-H69 and N592 SCLC cell lines from 50 to 200 U/ml/24 h IL-2) or with vector only, displayed no significant changes in HLA-class I expression to present endogenous antigens, we analyzed unmodified or IFN-␥ transfected cells for recognition by the CTL (not shown).
clone 297/22. This clone is specific for a MAGE-3-derived peptide (M3.271-279) presented by the HLA-A2 allele on Effect of IFN-␥ transfection on HLA-class I, ␤ 2 -microglobulin, and TAP mRNA expression melanoma cell lines. 21 As shown in Figure 5 , the unmodified or the IL-2-transfected N592 or NCI-H69 cell lines To investigate better the mechanisms of IFN-␥-mediated up-regulation of HLA class I surface molecules, we have were not recognized, while they induced a specific TNF level of the negative control MZ2-MEL, a melanoma cell line expressing HLA-A1 and MAGE-3. These data indicate that the transfection of the IFN-␥ gene into HLA class I-deficient SCLC cells convert them into cells able to present the TAA peptides to CTLs in a similar manner to well-known antigenic melanoma cell lines. In order to verify whether, as described for other TAPdeficient cell lines, incubation with HLA-binding peptides is able to enhance cell surface expression of HLA molecules, 22 NCI-H69 and N592 were incubated overnight with 100 m of M3.271-279 synthetic peptide. 21 Treated and untreated cells were analyzed by indirect immunofluorescence with the A2-specific mAb BB7.2. Incubation with the peptide did not significantly modify the low level of A2 expression (data not shown). However, the M3.271-279-pretreated NCI-H69 and N592 cell lines were able to induce a specific TNF release by the CTL-297/22 (Figure 6 ). In the same experiment incubation with the peptide did not affect recognition of the In this report, we show that SCLC cells frequently express mRNA for several CTL-defined tumor-associated 3/A2 + melanoma cell line. NCI-H69/IFN-␥ induced TNF secretion to a lower extent, that was however above the antigens. Perhaps more importantly, stable transfection they can bind to HLA-class I. 28, 29 In fact in a previous report the transfection of murine H-2 genes, together with a viral antigen gene, in SCLC cell lines did not result in the presentation of viral peptide to specific murine CTLs, owing to TAP deficiency. 25 Here we show that unmodified SCLC which display virtually no TAP mRNA expression, but detectable HLA-class I and ␤ 2 microglobulin mRNA, are unable to present endogenous MAGE-3 peptide to a specific A2-restricted CTL clone. The finding that IFN-␥ gene transfer induced an increased surface expression of HLA class I molecules and the ability to process and present an endogenous antigen-derived peptide to specific CTL, may be explained by the induction of TAP expression and possibly of other IFN-␥-inducible molecules involved in antigen processing. That the main defect relies on the endogenous antigen processing/transport pathway, is also suggested by the finding that the unmodified SCLC, loaded with a MAGE-3 synthetic peptide, were recognized by the CTL clone. This indicates that 'empty' HLA class I molecules may be present in unmodified cells, in presenting properties, in the absence of detectable IFN-␥ secretion, is in agreement with previous observations in The CTL-defined tumor antigens encoded by genes of the MAGE, BAGE and GAGE families have a major other tumor models. 30, 31 In view of the inhibitory effect of IFN-␥ on the proliferation of lymphocytes, the lack of interest in tumor immunotherapy, because these genes are not expressed in normal tissues with the exception of IFN-␥ secretion by cells engineered with both IL-2 and IFN-␥ genes may be a favorable characteristic. Thus, the the testis and placenta. 1 Thus, specific immunization with appropriate MAGE-1 or -3 synthetic peptides has IL-2 secreted may act in a paracrine fashion to induce proliferation of CTLs without any inhibition by IFN-␥. been attempted in selected melanoma patients, with promising preliminary results. 23 Similar immunotherapy Several approaches based on IL-2 associated with IFN-␥ gene transfer may be envisaged, such as the direct transapproaches may also be extended to other tumor histotypes expressing the same antigens. Our observation that fer of cytokine genes into tumor masses to initiate a local antitumor immune response. The subsequent endogenmost SCLC lines express MAGE-3 and also less frequently, MAGE-1 antigen, is in agreement with previous ous production of IFN-␥ during the immune response, eventually potentiated by a short treatment with recomfindings. 24 In addition, BAGE and GAGE appeared to be expressed on a substantial fraction of these tumors. These binant IFN-␥, may induce expression of HLA molecules by residual tumor cells and thus allow recognition by findings also suggested the possibility of inducing specific CTL responses in SCLC patients for immunotherapy CTLs. Another possibility is the use of IFN-␥/IL-2 engineered cellular vaccines to induce CTL responses. The purposes. However, SCLC often display a reduced expression of HLA-class I molecules, 20 and a deficient knowledge of the expression of defined TAA in a given tumor (ie MAGE-3) may allow the use of allogeneic presentation of antigenic peptides to CTLs has been reported in some SCLC cell lines. 25 These defects may tumor cells sharing relevant HLA restriction elements and TAA with selected patients. This may be particularly reflect the particularly aggressive and rapid course of this tumor and may hamper the development of CTL-based useful in SCLC, in view of the difficulty of obtaining autologous tumor cells due to the lack of surgical treatimmunotherapy. Indeed, the loss of MHC class I alleles has been related to tumor progression in several neoment indication. plasias and may represent a mechanism of escape from immune recognition. 26, 27 Genova, Italy) and a ␤ 2 microglobulin cDNA were 32 Plabeled by random priming and used for hybridization at 3 × 10 6 c.p.m./ml. RT-PCR analysis of MAGE-1 and 3, BAGE and GAGE expression Total RNA was isolated by the guanidium-isothio-TNF production by T cell clones and TNF assay Transfectants were tested for their ability to stimulate the cyanate/caesium chloride procedure. Two microgrammes of RNA were reverse-transcribed to cDNA production of TNF by the HLA-A2-restricted, MAGE-3-specific CTL clone 297/22, as described. 3 Briefly, 1500 using 0.5 g oligo (dT) [12] [13] [14] [15] [16] [17] [18] M3.271-279 (FLWGPRALV) 21 was purchased from PRIMM (Milan, Italy). The peptide was dissolved at 10 PCR was carried out in a Perkin Elmer 2400 DNA thermal cycler for 30 cycles (30 s at 94°C, 1 min 30 s at 72°C mm in DMSO, diluted further in 0.9% NaCl, and stored at −80°C. For the CTL stimulation test, SCLC and melafor MAGE-1; 30 s at 94°C, 2 min at 72°C for MAGE-3; 30 s at 94°C, 30 s at 65°C, 45 s at 72°C for ␤-actin; 30 s at noma cell lines were incubated overnight at 37°C in the presence of peptide (100 m). After extensive washing 94°C, 1 min at 56°C, 1 min 30 s at 72°C for GAGE). The cycling was concluded with a final extension at 72°C for the TNF assay was performed as described above. 7 min.
Ten microlitres of amplified products were analyzed
